×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

China Porcine Vaccines Market

ID: MRFR/Pharma/48725-HCR
200 Pages
Rahul Gotadki
February 2026

China Porcine Vaccines Market Research Report By Type (Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, DNA vaccines), By Disease Indication (PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine influenza, Aujeszky's disease (AD), Porcine Circovirus Associated Disease (PCVAD), Others) and By End-user (Veterinary Hospitals, Hog Production Farm) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

China Porcine Vaccines Market Infographic
Purchase Options

China Porcine Vaccines Market Summary

As per Market Research Future analysis, the China porcine vaccines market size was estimated at 144.0 $ Million in 2024. The China porcine vaccines market is projected to grow from 151.4 $ Million in 2025 to 250.0 $ Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.1% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The China porcine vaccines market is experiencing robust growth driven by technological advancements and increasing demand for disease prevention.

  • The largest segment in the China porcine vaccines market is the inactivated vaccines, which dominate due to their effectiveness.
  • The fastest-growing segment is the recombinant vaccines, reflecting a shift towards innovative solutions in disease management.
  • Rising demand for disease prevention is a key trend, as producers seek to enhance herd health and productivity.
  • Major market drivers include increasing livestock production and emerging infectious diseases, which necessitate effective vaccination strategies.

Market Size & Forecast

2024 Market Size 144.0 (USD Million)
2035 Market Size 250.0 (USD Million)
CAGR (2025 - 2035) 5.14%

Major Players

Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

China Porcine Vaccines Market Trends

the porcine vaccines market is experiencing notable growth, driven by increasing awareness of animal health and the rising demand for pork products. The emphasis on biosecurity measures in livestock farming has led to a heightened focus on vaccination programs. Farmers are increasingly recognizing the importance of immunization in preventing diseases that can significantly impact herd productivity and overall profitability. This trend is further supported by government initiatives aimed at enhancing animal health standards and ensuring food safety. As a result, the market is witnessing a surge in the development and adoption of innovative vaccine solutions tailored to address specific health challenges in swine populations. Moreover, advancements in vaccine technology are contributing to the evolution of the porcine vaccines market. The introduction of novel vaccine formulations and delivery methods is enhancing the efficacy and convenience of immunization practices. Additionally, the growing trend of precision livestock farming is enabling farmers to monitor animal health more effectively, allowing for timely vaccination interventions. This shift towards data-driven decision-making is likely to shape the future landscape of the market, as stakeholders seek to optimize health management strategies and improve overall herd performance. The combination of these factors suggests a promising outlook for the porcine vaccines market in the coming years.

Rising Demand for Disease Prevention

the porcine vaccines market is experiencing an increasing demand for vaccines aimed at preventing various swine diseases. This trend is largely driven by the need for enhanced biosecurity measures in livestock farming. Farmers are becoming more aware of the economic implications of disease outbreaks, prompting them to invest in vaccination programs to safeguard their herds.

Technological Advancements in Vaccine Development

Innovations in vaccine technology are playing a crucial role in shaping the porcine vaccines market. The development of new vaccine formulations and delivery systems is improving the effectiveness of immunization. These advancements are likely to facilitate better disease management and contribute to higher productivity in swine farming.

Government Support and Regulation

Government initiatives aimed at improving animal health standards are significantly influencing the porcine vaccines market. Regulatory frameworks are being established to ensure the safety and efficacy of vaccines. This support is encouraging manufacturers to invest in research and development, ultimately leading to a more robust market.

China Porcine Vaccines Market Drivers

Emerging Infectious Diseases

The emergence of new infectious diseases poses a substantial threat to the swine industry in China, thereby influencing the porcine vaccines market. Recent outbreaks of diseases such as African Swine Fever (ASF) have highlighted the vulnerability of pig populations. The need for effective vaccines to combat these diseases is becoming increasingly urgent. In response, the Chinese government and private sector are investing in research and development to create vaccines that can effectively mitigate these threats. The potential for significant economic impact from disease outbreaks underscores the necessity for robust vaccination programs, which may drive growth in the porcine vaccines market as producers seek to protect their herds.

Increasing Livestock Production

The rising demand for pork in China is driving the porcine vaccines market. As the population grows, the need for efficient livestock production intensifies. In 2025, pork consumption in China is projected to reach approximately 60 million metric tons, necessitating enhanced health management practices. Vaccination plays a crucial role in maintaining herd health and productivity, thereby supporting the overall growth of the porcine vaccines market. Farmers are increasingly recognizing the importance of vaccination in preventing disease outbreaks, which can lead to significant economic losses. Consequently, the focus on improving livestock production efficiency is likely to propel the demand for innovative vaccines tailored to the specific needs of the Chinese market.

Regulatory Framework Enhancements

The regulatory environment surrounding animal health in China is evolving, which is influencing the porcine vaccines market. The government is implementing stricter regulations to ensure the safety and efficacy of vaccines. These enhancements are aimed at improving the overall health of livestock and reducing the incidence of disease outbreaks. As a result, vaccine manufacturers are encouraged to innovate and comply with these regulations, leading to the development of more effective products. The increased focus on regulatory compliance may create opportunities for growth in the porcine vaccines market, as producers seek to align with government standards and improve herd health.

Rising Awareness of Animal Health

There is a growing awareness among Chinese farmers regarding the importance of animal health, which is positively impacting the porcine vaccines market. Educational initiatives and outreach programs are helping farmers understand the benefits of vaccination in preventing diseases and ensuring the well-being of their livestock. This shift in mindset is likely to lead to increased adoption of vaccination protocols, thereby enhancing herd immunity and productivity. As farmers become more informed about the economic advantages of maintaining healthy pigs, the demand for effective vaccines is expected to rise. This trend indicates a promising future for the porcine vaccines market as awareness continues to expand.

Technological Innovations in Vaccine Delivery

Technological advancements in vaccine delivery systems are transforming the porcine vaccines market. Innovations such as needle-free vaccination methods and improved adjuvants are enhancing the efficacy and ease of vaccine administration. These developments are particularly relevant in China, where large-scale pig farming operations require efficient vaccination strategies. The introduction of more user-friendly delivery systems may encourage greater adoption of vaccines among farmers, ultimately leading to improved herd health and productivity. As these technologies continue to evolve, they are likely to play a pivotal role in shaping the future landscape of the porcine vaccines market.

Market Segment Insights

By Type: Inactivated vaccines (Largest) vs. Live attenuated vaccines (Fastest-Growing)

In the China porcine vaccines market, inactivated vaccines dominate the landscape, accounting for a significant portion of the market share due to their established effectiveness and safety profile. Live attenuated vaccines, while smaller in market share, are rapidly gaining traction due to their potency and ability to induce long-lasting immunity, making them an attractive option for swine producers looking for efficient solutions. The growth trends in this segment are driven by increasing demand for food safety and the rising prevalence of swine diseases, pushing producers towards effective vaccination strategies. Furthermore, government initiatives aimed at improving livestock health and productivity are fueling investments in vaccine R&D, leading to innovations in live attenuated and recombinant vaccine technologies that promise to enhance the efficacy of disease control in the swine population.

Inactivated vaccines (Dominant) vs. Live attenuated vaccines (Emerging)

Inactivated vaccines remain the dominant player in the China porcine vaccines market due to their long-standing reputation for effectiveness and comprehensive safety. They are typically used as a primary preemptive measure against various infectious diseases in swine, leveraging inactivated pathogens to stimulate immunity without causing disease. Conversely, live attenuated vaccines are emerging as a popular choice among producers looking for solutions that provide strong immunity with minimal doses. These vaccines use weakened forms of pathogens to elicit robust immune responses, making them particularly appealing for their efficiency and cost-effectiveness in large scale operations. This growing interest in live attenuated vaccines reflects a shift towards advanced, efficient vaccination methods in swine production.

By Disease Indication: PRRS (Largest) vs. PED (Fastest-Growing)

In the China porcine vaccines market, the disease indication segment is predominantly led by Porcine Reproductive & Respiratory Syndrome (PRRS), which holds the largest market share due to its widespread prevalence and significant impact on swine health. Porcine Epidemic Diarrhea (PED) follows as a notable contender, gaining traction rapidly in recent years. The market also includes other diseases such as Swine influenza, Aujeszky's disease, and Porcine Circovirus Associated Disease; however, they command smaller shares compared to PRRS and PED. The growth trends in the disease indication segment are largely driven by increasing awareness among farmers about the health implications of swine diseases and the economic benefits of vaccination. Furthermore, advancements in vaccine technologies and growing government initiatives to support the swine industry are anticipated to bolster the demand for PED vaccines, making it one of the fastest-growing segments in the market. Emerging strains and the need for effective disease management solutions also contribute significantly to the rising interest in this segment.

PRRS (Dominant) vs. PED (Emerging)

PRRS is recognized as the dominant disease indication in the China porcine vaccines market, characterized by its extensive impact on reproductive and respiratory health in swine. This condition results in significant economic losses for farmers, which underlines the critical role of vaccination. Conversely, PED, while still emerging, has garnered increased attention due to its rapid onset and high mortality rates in young pigs. The swift adaptation of vaccine formulations to combat PED highlights its rising importance in the market. Both segments are characterized by ongoing research and development for more effective vaccines, driven by the need for sustainable livestock management practices in the face of evolving disease threats.

By End-user: Veterinary Hospitals (Largest) vs. Hog Production Farm (Fastest-Growing)

In the China porcine vaccines market, the market share is significantly skewed towards veterinary hospitals, which cater to a wide range of animal health needs and have established networks for vaccine distribution. This segment dominates due to the solid infrastructure and consistency in service provision, thus attracting a larger clientele. In contrast, hog production farms, while currently smaller in terms of share, are rapidly expanding, reflecting the agricultural push for larger-scale operations and enhanced biosecurity measures in livestock health management. The growth trends are particularly favorable for hog production farms, driven by increasing investment in livestock and the rising demand for pork in China. Farmers are becoming more aware of vaccination's vital role in maintaining herd health and productivity, leading to increased adoption rates. Additionally, government initiatives aiming at boosting agricultural productivity and biosecurity practices contribute to the expansion of this segment, positioning it as the fastest-growing in the market.

Veterinary Hospitals (Dominant) vs. Hog Production Farm (Emerging)

Veterinary hospitals in the China porcine vaccines market are characterized by their established presence, comprehensive service offerings, and pivotal role in animal healthcare. They leverage advanced technologies and skilled professionals to deliver efficient vaccination programs, thus ensuring livestock are protected from prevalent diseases. This domination is complemented by strong relationships with food supply chains and a loyal customer base. On the other hand, hog production farms are emerging due to the growing emphasis on biosecurity and herd management. These farms are increasingly adopting vaccines to mitigate disease risks and enhance production efficiency. As the local pig farming industry becomes more industrialized, the importance of these farms in the overall vaccine market landscape is set to rise, attracting new investments and fostering innovation.

Get more detailed insights about China Porcine Vaccines Market

Key Players and Competitive Insights

The porcine vaccines market in China is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Zoetis (US), Merck Animal Health (US), and Boehringer Ingelheim (DE) are at the forefront, leveraging their extensive research capabilities and established market presence to drive growth. These companies appear to focus on developing advanced vaccine formulations and enhancing their distribution networks, which collectively fosters a dynamic competitive environment. The emphasis on innovation and strategic collaborations among these firms suggests a trend towards more sophisticated vaccine solutions tailored to the specific needs of the Chinese market.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. This approach not only enhances responsiveness to market demands but also aligns with the growing emphasis on sustainability. The market structure is moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. Their ability to optimize supply chains and localize production is likely to set them apart in a competitive landscape that demands agility and responsiveness.

In October Zoetis (US) announced the launch of a new vaccine specifically targeting Porcine Reproductive and Respiratory Syndrome (PRRS), a significant disease affecting swine health. This strategic move underscores Zoetis's commitment to addressing critical health challenges in the porcine sector, potentially enhancing its market share in China. The introduction of this vaccine is expected to bolster the company's portfolio and reinforce its position as a leader in swine health solutions.Similarly, in September 2025, Merck Animal Health (US) expanded its partnership with local Chinese veterinary institutions to enhance research and development capabilities. This collaboration aims to accelerate the development of vaccines tailored to regional disease challenges. By investing in local partnerships, Merck is likely to strengthen its foothold in the Chinese market, ensuring that its products are well-suited to the specific needs of local farmers and veterinarians.

In August Boehringer Ingelheim (DE) launched a digital platform aimed at improving vaccine management and tracking for swine producers. This initiative reflects a broader trend towards digitalization in the agricultural sector, where technology is increasingly integrated into traditional practices. By providing farmers with tools to monitor vaccine efficacy and animal health, Boehringer Ingelheim is positioning itself as a forward-thinking leader in the market, likely enhancing customer loyalty and operational efficiency.

As of November the competitive trends in the porcine vaccines market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market dynamics. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and reliable supply chains. This shift may ultimately lead to a more resilient and responsive market, better equipped to meet the challenges of the future.

Key Companies in the China Porcine Vaccines Market include

Industry Developments

Recent developments in the China Porcine Vaccines Market have been dynamic, particularly with a growing emphasis on the prevention of diseases like African Swine Fever (ASF). This has led companies like Zoetis and Boehringer Ingelheim to enhance their product portfolios, resulting in overall increased market growth. In 2022, the market valuation significantly rose, driven by rising awareness of animal health and intensifying production practices. Notably, in September 2023, CEVA Animal Health announced an expansion of their vaccine offerings in China, aiming to cater to the burgeoning demand for effective porcine vaccines. 

In terms of mergers and acquisitions, in October 2023, Vetoquinol acquired a minority stake in Herd Health Biosecurity, signaling consolidation in the market to address health challenges better facing the porcine industry. This strategic move is expected to improve product development and distribution capabilities. Additionally, the China Animal Husbandry Industry Co has been actively integrating new technologies into vaccine research, which is further propelling the market forward in terms of innovation. The focus remains not only on existing diseases but also on increasing biosecurity measures across the livestock sector in China to ensure long-term sustainability and health management.

Future Outlook

China Porcine Vaccines Market Future Outlook

The Porcine Vaccines Market in China is projected to grow at a 5.14% CAGR from 2025 to 2035, driven by increasing demand for disease prevention and advancements in vaccine technology.

New opportunities lie in:

  • Development of customized vaccine formulations for specific regional diseases.
  • Expansion of digital platforms for vaccine tracking and management.
  • Investment in R&D for next-generation vaccines targeting emerging pathogens.

By 2035, the porcine vaccines market is expected to achieve robust growth and enhanced market dynamics.

Market Segmentation

China Porcine Vaccines Market Type Outlook

  • Inactivated vaccines
  • Live attenuated vaccines
  • Toxoid vaccines
  • Recombinant vaccines
  • Conjugate vaccines
  • DNA vaccines

China Porcine Vaccines Market End-user Outlook

  • Veterinary Hospitals
  • Hog Production Farm

China Porcine Vaccines Market Disease Indication Outlook

  • PED (Porcine Epidemic Diarrhea)
  • PRRS (Porcine Reproductive & Respiratory Syndrome)
  • Swine influenza
  • Aujeszky's disease (AD)
  • Porcine Circovirus Associated Disease (PCVAD)
  • Others

Report Scope

MARKET SIZE 2024 144.0(USD Million)
MARKET SIZE 2025 151.4(USD Million)
MARKET SIZE 2035 250.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.14% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR)
Segments Covered Type, Disease Indication, End-user
Key Market Opportunities Advancements in vaccine technology enhance disease control in the porcine vaccines market.
Key Market Dynamics Rising demand for innovative porcine vaccines driven by regulatory changes and heightened biosecurity concerns in livestock management.
Countries Covered China
Leave a Comment

FAQs

What is the expected market size of the China Porcine Vaccines Market in 2024?

The China Porcine Vaccines Market is expected to be valued at 160.0 USD Million in 2024.

What will the market value of the China Porcine Vaccines Market be by 2035?

By 2035, the market value is projected to reach 375.0 USD Million.

What is the expected CAGR for the China Porcine Vaccines Market from 2025 to 2035?

The expected CAGR for the market is 8.051% during the forecast period from 2025 to 2035.

Which type of vaccine is expected to dominate the market by 2035?

Inactivated vaccines are anticipated to dominate the market, valued at 110.0 USD Million in 2035.

What is the growth rate for live attenuated vaccines in the China Porcine Vaccines Market?

Live attenuated vaccines are projected to grow from 40.0 USD Million in 2024 to 90.0 USD Million in 2035.

Who are the key players in the China Porcine Vaccines Market?

Major players in the market include CEVA Animal Health, Merial, Zoetis, and Boehringer Ingelheim.

What is the estimated market size for toxoid vaccines in 2024?

The market size for toxoid vaccines is estimated to be 30.0 USD Million in 2024.

Which segment of the China Porcine Vaccines Market is expected to showcase the highest growth?

Recombinant vaccines are forecasted to show significant growth, increasing from 20.0 USD Million in 2024 to 50.0 USD Million in 2035.

How does the market for conjugate vaccines evolve from 2024 to 2035?

The market for conjugate vaccines is expected to rise from 20.0 USD Million in 2024 to 60.0 USD Million in 2035.

What are some potential challenges in the China Porcine Vaccines Market?

Key challenges may include regulatory changes and competition from alternative health solutions for pigs.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions